计算溶液所需的质量、体积或浓度。
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers.
In Vitro
NSC745885 (0.5-4 μM; 24, 48 or 72 hours) has a growth inhibitory or death-promoting effect on the SAS cells, it significantly decreases the\ndensities of cultured cells when compared with untreated cells. The IC 50 of NSC745885 is 0.85 μM after 72 hours’ treatment. NSC745885 (0.5-4 μM; 24 hours) increases annexin V positive cells in a dose-dependent manner, and the differences appears as a dose-dependent manner. NSC745885 (0.5-2 μM; 24 or 48 hours) decreases XIAP protein levels and increases protein levels both as a dose-dependent manner in SAS cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: SAS cells is obtained from a poorly differentiated human squamous cell carcinoma Concentration: 0.5 μM, 1 μM, 1.5 μM, 2 μM, 4 μM Incubation Time: 24, 48, or 72 hours Result: Decreases SAS cells growth as a time and dose-dependent manner. Apoptosis AnalysisCell Line: SAS cells is obtained from a poorly differentiated human squamous cell carcinoma Concentration: 0.5 μM, 1 μM, 1.5 μM, 2 μM, 4 μM Incubation Time: 24 hours Result: Decreases SAS cells growth as a time and dose-dependent manner. Western Blot AnalysisCell Line: SAS cells is obtained from a poorly differentiated human squamous cell carcinoma Concentration: 0.5 μM, 1 μM, 1.5 μM, 2 μM Incubation Time: 24 or 48 hours Result: Increased cleaved caspase-3 expression and decreased XIAP expression.
In Vivo
NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Eight-week-old NOD/SCID (NOD.CB17 Prkdc scid /J) mice Dosage: 2 mg/kg Administration: Intraperitoneal injection; 2 mg/kg; once daily; 10 days Result: Inhibited engrafted tumors growth in vivo.
Form:Solid
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 苯类化合物 |
| 类(Class) | 蒽 |
| 亚类(Subclass) | 蒽醌 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 蒽醌 |
| 其他上位类(Alternative Parents) | 苯并噻二唑 芳基酮 噻二唑类 杂芳族化合物 氮杂环化合物 有机氮化合物 有机氧化物 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 2,1,3-苯并噻二唑 - 9,10-蒽醌 - 蒽醌 - 芳香族杂多环化合物 - 芳基溴化物 - 氮杂环 - 吡唑 - 杂芳香族化合物 - 烃衍生物 - 酮 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 噻二唑 |
| 描述(Description) | 该化合物属于有机化合物中的蒽醌类。这类有机化合物含有蒽醌-9,10-二醌、1,4-蒽醌或1,2-蒽醌。 |
| 外部描述符(External Descriptors) | 暂无 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|